ValuEngine cut shares of Oncolytics Biotech Inc. (OTCMKTS:ONCYF) from a hold rating to a sell rating in a research note published on Friday morning.

Oncolytics Biotech (OTCMKTS:ONCYF) traded up 0.75% during midday trading on Friday, hitting $0.41. The company had a trading volume of 33,326 shares. Oncolytics Biotech has a 52-week low of $0.14 and a 52-week high of $0.85. The stock has a 50 day moving average of $0.40 and a 200 day moving average of $0.46. The firm’s market cap is $57.16 million.

TRADEMARK VIOLATION NOTICE: This report was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/02/oncolytics-biotech-inc-oncyf-downgraded-to-sell-at-valuengine.html.

About Oncolytics Biotech

Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.

Receive News & Stock Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related stocks with our FREE daily email newsletter.